Setipiprant for Androgenetic Alopecia in Males: Results from a Randomized, Double-Blind, Placebo-Controlled Phase 2a Trial

PURPOSE: To evaluate oral setipiprant versus placebo for scalp hair growth in men with androgenetic alopecia (AGA). PATIENTS AND METHODS: Males aged 18 to 49 years with AGA were enrolled in a double-blind, multicenter, 32-week, phase 2a trial; randomized to twice-daily (BID) 1000-mg (2×500 mg for a...

Descripción completa

Detalles Bibliográficos
Autores principales: DuBois, Janet, Bruce, Suzanne, Stewart, Daniel, Kempers, Steven, Harutunian, Christy, Boodhoo, Terry, Weitzenfeld, Amy, Chang-Lin, Joan-En
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Clinical Trial Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8526366/
https://www.ncbi.nlm.nih.gov/pubmed/34703265
http://dx.doi.org/10.2147/CCID.S319676

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8526366/
https://www.ncbi.nlm.nih.gov/pubmed/34703265
http://dx.doi.org/10.2147/CCID.S319676

Ejemplares similares